Prostate Cancer Research Highlights (2025 - 2026)

Prostate cancer is the second most commonly diagnosed cancer in men globally and a leading cause of cancer-related mortality. Despite widespread prostate-specific antigen (PSA) screening and advances in systemic therapies, clinical outcomes vary widely, particularly in metastatic and castration-resistant disease. Traditional research paradigms have emphasized pharmacologic intervention after disease onset; however, recent evidence increasingly highlights the importance of modifiable risk factors, structural inequities, and metabolic health.

At the same time, patient-driven experimentation with repurposed drugs—often outside conventional clinical trials—has gained visibility, raising important scientific and ethical questions. This resource page compiles an integrated update across prevention, treatment, and emerging off-label approaches.

Risk Factors and Prevention

Treatment 

Clinical Trials of Metastatic Prostate Cancer

There are more than 3,000 clinical trials of ClinicalTrials.gov on metastatic prostate cancer.

Case Reports (Repurposed Drugs)

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer: Dr. William Makis Protocol Explained (2026 Guide)

Image
Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated:  October 2026 Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here. Quick Answer (AI & Search Summary) Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ...
Read more

Top 20 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Image
Medically reviewed by Dr. Frank Yap, MD  |  Written by OneDayMD Editorial Team  |  Last updated October 2026 Quick Answer No single dietary supplement is established as a universal cancer treatment. Of the 17 supplements reviewed here, the deepest human evidence supports vitamin D3 (with K2 and magnesium) , polysaccharide-K (PSK) from turkey tail as an add-on to chemotherapy in Japanese trials, berberine for preventing colorectal adenoma recurrence, omega-3 fatty acids , curcumin and green tea EGCG . Even these show mixed rather than uniformly positive results. Melatonin looked promising in small trials, but the largest randomized trial found no benefit in early-stage lung cancer. A few supplements, namely high-dose beta-carotene, vitamin E and long-term high-dose B6/B12 , have been linked to higher cancer risk in specific groups. No supplement replaces conventional cancer treatment, and antioxidant pills are generally discouraged during chemo...
Read more

Dr. William Makis's Recommended Ivermectin, Fenbendazole and Mebendazole Dosages for Cancer (2026)

Image
Last revised: August 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: October 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  Together, ivermectin and mebendazole exhibit 37 distinct anticancer mechanism classes across 25 human malignancies, highlighting their exceptionally broad potential for therapeutic repurposing in oncology. Both are oral, widely available generic drugs that are well-tolerated alongside chemotherapy. Large, prospective, double-blind, parallel-group, randomized trials of combination ivermectin-mebendazole are urgently needed across a broad array of human malignancies. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discus...
Read more

Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide

Image
A Master Guide & Reference — Evidence, Mechanisms, Clinical Trials, Case Series, Safety, and Protocols By Dr. Frank Yap, MD · Originally published July 2025 · Reviewed and substantially updated September 2026 Quick Answer Ivermectin, fenbendazole, mebendazole, and niclosamide are antiparasitic drugs with laboratory and animal evidence of anticancer activity, plus a growing body of patient-reported case reports. None of the four is an approved or established cancer treatment.  Mebendazole and niclosamide have gone further into human oncology trials than fenbendazole, but results remain mixed or inconclusive. This guide organizes the mechanistic evidence, clinical trial data, 760+ compiled case reports, safety findings, and the updated Joe Tippens Protocol into one evidence-tiered reference — with the regulatory and safety picture current as of September 2026. Table of Contents Front Matter Introduction: The Joe Tippens Story Part I — The Case for Drug Repurposing...
Read more

Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective

Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated: September 2026 Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are l...
Read more

Fenbendazole, Ivermectin & Mebendazole for Lung Cancer: Critical Evidence Review of 63 Publicly Reported Cases (2026)

Image
Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinician...
Read more

Ivermectin Dosage for Cancer in 2026: Marik vs Makis vs Hope — What the Numbers Actually Are

Image
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Important disclaimer This article is educational. It is not a prescription and not a substitute for care from a licensed clinician. Ivermectin is FDA-approved for selected parasitic infections. Fenbendazole is a veterinary drug and is not approved for human use. Neither agent is approved to treat cancer. Do not self-medicate. Do not replace surgery, radiation, endocrine therapy, targeted therapy, immunotherapy, or chemotherapy that is working. High-dose daily ivermectin can cause neurologic toxicity. Any off-label use requires a physician, baseline labs, and a stop plan. Why this article exists Patients keep asking the same question: how many milligrams? The answers now disagree in public. In September 2024, Baghli, Makis, Marik and colleagues published a hybrid orthomolecular protocol in the Journal of Orthomolecular Medicine that listed ive...
Read more

Repurposed Cancer Drugs, Integrative & Precision Oncology (2026): Evidence Guide

Image
An evidence-aware guide to off-label cancer therapies, integrative oncology, precision oncology and emerging research, without hype or false promises. By Dr. Frank Yap, MD · One Day Media Network · Originally published January 2026 · Updated October 6, 2026 · Evidence reviewed to this date Quick Answer Repurposed cancer drugs are existing approved medicines tested for anti-cancer effects. As of October 2026, only one has recent randomized-trial support in a defined setting : low-dose aspirin after surgery for PI3K-pathway-altered stage I–III colorectal cancer (ALASCCA, NEJM 2025). Metformin failed in the 3,649-patient MA.32 breast cancer trial. Ivermectin, fenbendazole and mebendazole have no completed randomized trials showing cancer benefit. Repurposed drugs are adjuncts to, never replacements for, standard oncology care. Contents What this hub covers Executive summary Why repurposed drugs matter in oncology Evidence scale used on OneDayMD (CEBM Levels 1–5) Evi...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Archive

Show more